TiGenix : to present at BIO CEO & Investor Conference & key meetings in H1 2014
JANUARY 21, 2014
TiGenix to present at BIO CEO & Investor Conference & key meetings in H1 2014
Leuven (BELGIUM) - January 21, 2014 - TiGenix (NYSE Euronext: TIG), a leader in
the field of cell therapy, announced today that Eduardo Bravo, CEO, will be
presenting at the 16th Annual BIO CEO & Investor Conference. Hosted by the
Biotechnology Industry Organization (BIO), the BIO CEO & Investor Conference
will take place February 10-11 at the Waldorf Astoria in New York City.
Additionally, during the first half of 2014 the company will present at a number
of key events in Europe and the U.S. geared at investor and industry audiences.
February 10-11
BIO CEO & Investor Conference, The Waldorf Astoria, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
February 18
9th Annual Stem Cell Summit, The Convene, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
March 4-5
European Life Science CEO Forum, Airport Hilton, Zurich, Switzerland
Presenter: Eduardo Bravo, CEO
March 10-12
BIO-Europe Spring, Conference Center OVAL Lingotto, Turin, Italy
Attendees: Eduardo Bravo, CEO - Claudia Jiménez, Senior Director Corporate
Development
March 20
KBC Healthcare Conference, Brussels, Belgium
Attendees: Eduardo Bravo, CEO - Claudia D'Augusta, CFO
March 22
RegenMed Investor Day, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
March 27
BioCapital, The Grand, Amsterdam, the Netherlands
Presenter: Claudia D'Augusta
March 31 - April 1
7(th) Annual Kempen & Co Healthcare Conference, Amsterdam, the Netherlands
Attendees: Eduardo Bravo, CEO - Claudia D'Augusta, CFO
April 7-8
9(th) edition European Smallcap Event, Paris, France
Attendees: Eduardo Bravo, CEO - Claudia D'Augusta, CFO
May 20-22
9(th) Annual World Stem Cell & Regenerative Medicine Congress, London, UK
Presenter: Eduardo Bravo, CEO
May 21-22
BioEquity Europe 2014, Amsterdam, the Netherlands
Presenter: Claudia D'Augusta, CFO
June 23-26
Bio International Convention, San Diego, U.S.
Attendees: Eduardo Bravo, CEO - Claudia Jiménez, Senior Director Corporate
Development
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com
Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect®, and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via GlobeNewswire
[HUG#1755757]